Harnessing the immune response in exceptionally long-term survivors to develop novel therapeutics

This $439,912 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Provincial Health Services Authority, operating as BC Cancer, a major Canadian healthcare organization specializing in cancer research, treatment, and prevention.

The grant aims to "HARNESSING THE IMMUNE RESPONSE IN EXCEPTIONALLY LONG-TERM SURVIVORS TO DEVELOP NOVEL THERAPEUTICS", leveraging BC Cancer's expertise in cancer care and research to contribute to cutting-edge biomedical research in oncology, particularly in areas such as genomics, precision medicine, and immunotherapy. As a prime and sub-awardee, BC Cancer conducts comprehensive research projects and provides specialized expertise in precision oncology, genomic analysis, molecular pathology, and bioinformatics to collaborative efforts with prominent U.S. institutions across various cancer types. This project grant runs from May 1, 2024 to April 30, 2027.